Completed

4

80

 

Heart failure (routine therapy including positive inotropic drugs, diuretics and vasodilator, angiotensin converting enzyme inhibitors, beta-blockers, phosphodiesterase inhibitors, etc.) ;levosimendan +conventional treatment

Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Science and technology projects of Shandong Province

chronic heart failure

 

 

Recruiting

4

180

 

Heart failure (routine therapy including positive inotropic drugs, diuretics and vasodilator, angiotensin converting enzyme inhibitors, beta-blockers, phosphodiesterase inhibitors, etc.) ;On the basis of routine therapy heart failure combined with creatine phosphate ;On the basis of routine therapy heart failure combined with Levosimendan ;On the basis of routine therapy heart failure combined with Recombinant Human Brain Natriuretic Peptideon

Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Science and technology projects of Shandong Province

chronic heart failure

 

 

Ongoing

4

20

Europe

Simdax, Simdax, Simdax

Tays/ anestesiayksikkö

Leikkaushoitoa vaativa elektiivinen aortta-aneyrymapotilas

 

 

Ongoing

4

20

Europe

Simdax, Simdax

University Medical Centre Ljubljana

advanced chronic heart failure

 

 

Ongoing

4

30

Europe

Simdax 2.5 mg/mL, no, Simdax 2.5 mg/mL, Simdax 2.5 mg/mL

Helsinki University Central Hospital

Sepelvaltimotauti I20.0Sydämen vajaatoiminta I50.0

 

 

Completed

4

80

Europe

SIMDAX, Not applicable, Infusion, Simdax

Semmelweis University, Heart and Vascular Center, Semmelweis University

A total of 80 symptomatic patients with severe ischaemic or non-ischaemic cardiomyopathy will be enrolled in the study. Those, who were implanted a device and proved to be non-responders or low responders with ischaemic etiology would be separetly investigated. A vizsgálatba összesen 80 tünetes, előrehaladott szisztolés szívelégtelenségben (iszkémiás vagy nem iszkémiás cardiomyopathia) szenvedő beteg bevonását tervezzük. A korábban kardiális reszinkronizációs pacemaker/defibrillátor (CRT-P/CRT-D) beültetésen átesett non-responder vagy low-responder, iszkémiás cardiomyopathiában szenvedő betegeket külön csoportként kezeljük., Patients with severe heart failure symptoms and ischaemic or non-ischaemic etiology will be enrolled in the study. Előrehaladott szisztolés szívelégtelenségben (iszkémiás vagy nem iszkémiás cardiomyopathia) szenvedő betegek vizsgálatát tervezzük., Diseases [C] - Cardiovascular Diseases [C14]

 

 

Completed

4

40

Europe

Simdax (Levosimendan), Concentrate for solution for infusion, Simdax

Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB), Verein zur Förderung der Forschung auf dem Gebiet der Arteriosklerose, Thrombose und vaskulären Biologie (ATVB)

Advanced heart failure, Long time heart failure, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Completed

4

30

Europe

Simdax, Concentrate and solvent for solution for infusion, Simdax

Sahlgrenska Universitetssjukhuset/Sahlgrenska, Sahlgrenska Academy

Acute kidney injury postoperatively in connection with heart surgery Akut njursvikt i samband med hjärtkirurgi, Acute renal failure Akut njursvikt, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Completed

4

42

Europe

Simdax, Concentrate and solvent for solution for infusion, Simdax

Heart Center, Department of Cardiology, Rigshospitalet, Heart Center, Department of Cardiology, Rigshospitalet

Advanced chronic heart failure, Severe chronic reduced heart function, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Terminated

4

350

Europe

Simdax, Concentrate and solvent for concentrate for solution for infusion, Simdax

Uniwersytet Medyczny w Białymstoku, Medical Research Agency

Ambulatory Heart Failure Patients Ambulatoryjni chorzy z ciężką skurczową niewydolnością serca, Heart Failure Choroba serca, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Enrolling by invitation

4

470

RoW

Regular management+Levosimendan

Qilu Hospital of Shandong University

Early Management, Acute Heart Failure, NSTEMI - Non-ST Segment Elevation MI

12/21

12/21

Not yet recruiting

4

600

 

Levosimendan ;Placebo

Shandong Provincial Hospital; Shandong Provincial Hospital, self-financing

Cardiovascular disease

 

 

Recruiting

4

40

 

Intravenous infusion of levosimendan ;Intravenous infusion of levosimendan

The First Affiliated Hospital, Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University, China Foundation for International Medical Exchange

Cardiac failure

 

 

Recruiting

4

136

RoW

levosimendan

Tongji Hospital

Heart Failure

06/22

06/22

Recruiting

4

1146

 

Levosimendan ;placebo

Fuwai Hospital; Fuwai Hospital, Sponsor funding

heart failure

 

 

Not yet recruiting

4

120

 

standard heart failure therapy ;standard heart failure therapy combined with levosimendan and dopamine

The First Affiliated Hospital of Sun Yat-Sen University; The First Affiliated Hospital of Sun Yat-Sen University, China International Medical Foundation

Heart failure

 

 

Ongoing

4

10

Europe

dobutamina, Levosimendan, Concentrate and solvent for concentrate for solution for infusion, Dobutamina, Simdax

Germans Trias i Pujol Health Research Institute, Germans Trias i Pujol Health Research Institute

Heart failure patients with depressed left ventricular ejection fraction Pacientes con insuficiencia cardiaca con fracción de eyección del ventrículo izquierdo deprimida, Heart failure patients with diminished cardiac function Pacientes con insuficiencia cardiaca reducida, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Completed

4

40

RoW

Saline Solution, Nacl 0.9 %, Levosimendan, Magnesium Sulfate

Dalia Saad Abd-El Kader, Cairo University

Aortic Coarctation

03/23

04/23

Recruiting

4

108

 

Levosimendan ;Placebo

Qilu Hospital of Shandong University; Shandong University Qilu Hospital, Special funds and self-raised funds

Sarcopenia with heart failure with reduced ejection fraction

 

 

Recruiting

4

1000

RoW

protective ventilation, prone position ventilation, glucocorticoid therapy, Dexamethasone, Hydrocortisone, restrictive fluid resuscitation, Thymosin Alpha, Muscle relaxant therapy, Vecuronium Bromide, Succinylcholine, Integrated Chinese and Western Medicine Treatment, statin therapy, Simvastatin, Rosuvastatin, anti-infective treatment, Extracorporeal Membrane Oxygenation（ECMO）, stem cell therapy, Sedative analgesia/muscle relaxant therapy, Propofol, midazolam, dexmedetomidine, inotropes therapy, Dopamine, Olprinone, Levosimendan, Vasoactive drug therapy, Norepinephrine, epinephrine, metaraminol, isoproterenol

Second Affiliated Hospital, School of Medicine, Zhejiang University, Renmin Hospital of Wuhan University, The Second Affiliated Hospital of Harbin Medical University, West China Hospital, The First Affiliated Hospital of Zhengzhou University, Peking Union Medical College Hospital, Wuhan Union Hospital, China, Fudan University, Guangdong Provincial People's Hospital, Ningbo No. 1 Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University

Acute Respiratory Distress Syndrome

10/23

12/23

Recruiting

4

112

RoW

Levosimontane injection, wen，yue

Qilu Hospital of Shandong University

Heart Failure, Aortic Stenosis, Severe

01/25

02/25

Terminated

4

70

Europe

Levosimendan, Placebo

Medical University of Bialystok, Medical Research Agency, Poland, University of Opole, Medical University of Lodz, Poznan University of Medical Sciences, Nicolaus Copernicus University, National Institute of Cardiology, Warsaw, Poland, Azienda Ospedaliera dei Colli, John Paul II Specialist Hospital in Kraków

Heart Failure New York Heart Association Class III, Heart Failure New York Heart Association Class IV, Heart Failure, Systolic, Heart Failure With Reduced Ejection Fraction

02/24

08/24

Not yet recruiting

4

50

 

After completing the examination, the enrolled subjects were treated with levosimendan, with a starting dose of 0.1 μ G/kg/min, without limiting the side effects of speed (such as hypotension and tachycardia), the dosage can be increased to 0.2 after 2-4 hours μ G/kg/min, ensuring a total infusion time of 20-24 hours and a total dose of 12.5mg.; After completing the examination, the enrolled subjects were treated with dobutamine, with a starting dose of 5 μ G/kg/min, if MAP can be maintained at a normal level (MAP ≥ 65mmHg), maintain this infusion dose unchanged and continue infusion for 24 hours.

The First Affiliated Hospital of China Medical University; The First Affiliated Hospital of China Medical University, China International Medical Exchange Foundation

Septic cardiomyopathy

 

 

Recruiting

4

250

Europe

levosimendan, Soluvit, Standard care

08/27

08/28

Recruiting

4

100

 

Levosimendan in addition to standard therapy ; Standard therapy

the First Hospital of Jilin University.; the First Hospital of Jilin University., the First Hospital of Jilin University.

ischemic stroke

 

 

Ongoing

3

36

Europe

levosimendan, C01CX., Concentrate for solution for infusion, SIMDAX

FUNDACION PARA LA INVESTIGACIÓN BIOSANITARIA DE ANDALUCIA ORIENTAL_ FPA, Hospital Virgen de las Nieves

Children aged 1 month to 14 years in the health area of the province of Granada who will be undergoing heart surgery with a clinical high risk of developing acute heart failure after surgery, treated at the Unit Pediatric Intensive Care, University Hospital Virgen de las Nieves., Children with congenital heart disease that will be operate., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

 

 

Ongoing

3

60

Europe

Simdax, Simdax

Fundación Investigación y Desarrollo en el Área Cardiovascular

Analysis of the short-term treatment with levosimendan, a cardiac stimulant drug, of the acute exacerbation of chronic heart failureEstudio del tratamiento a corto plazo con levosimendan, fármaco estimulante cardiaco, de la descompensación aguda de la insuficiencia cardiaca crónica

 

 

Completed

3

206

Europe

ZIMINO 12.5 mg (levosimendan) 2,5 mg/ml, Solution for infusion, ZIMINO 12.5 mg (levosimendan) 2,5 mg/ml

ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP), DGOS

Adult patients with acute cardiogenic shock refractory to conventional therapy placed on VA-ECMO support and for whom withdrawal from ECMO is possible. Patients adultes assistés par VA-ECMO pour choc cardiogénique réfractaire au traitement conventionnel et pour lesquels un sevrage de l’ECMO est envisageable., Adult patients with acute cardiogenic shock refractory to conventional therapy placed on VA-ECMO support and for whom withdrawal from ECMO is possible. Patients adultes assistés par VA-ECMO pour choc cardiogénique réfractaire au traitement conventionnel et pour lesquels un sevrage de l’ECMO est envisageable., Diseases [C] - Cardiovascular Diseases [C14]

 

 

Recruiting

3

112

RoW

Simdax

Yooyoung Pharmaceutical Co., Ltd.

Acute Decompensated Heart Failure

01/22

07/22

Completed

3

230

Europe

Levosimendan, Placebo

Medical University of Vienna

Cardiovascular Risk Factor

11/23

12/24

Not yet recruiting

3

190

Europe

Simdax, Concentrate for solution for infusion, Simdax

Medical University of Gdańsk, Medical Research Agency

Takotsubo syndrome (TTS), also known as apical ballooning syndrome, Takotsubo cardiomyopathy, broken heart syndrome, and stress-induced cardiomyopathy, is a rare condition and accounts for 1–3% of all patients referred to hemodynamic laboratories with a primary diagnosis of acute coronary syndrome (ACS)., Takotsubo syndrome, Diseases [C] - Cardiovascular Diseases [C14]

 

 

Completed

3

206

Europe

Levosimendan, Placebo of Levosimendan

Assistance Publique - Hôpitaux de Paris, DGOS

Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication

11/24

11/24

Recruiting

3

230

Europe

Levosimendan, Experimental arm, PLACEBO, Control arm

Assistance Publique - Hôpitaux de Paris, DGOS - French Ministry of Health

Patients Referred for an Isolated or a Combined Surgical Correction of Functional Moderate to Severe Tricuspid

01/25

01/25

Recruiting

3

540

Europe, US, RoW

TNX-103, Placebo

Tenax Therapeutics, Inc.

Pulmonary Hypertension Associated With HFpEF

06/28

06/29

Recruiting

2/3

300

Europe

Levosimendan, SIMDAX, Placebos

María de los Ángeles Tena Pajuelo, Orion Corporation, Orion Pharma, Canary Foundation, Dr Negrin Hospital Statistician, Dr Negrin Hospital Farmacy, CRO TRIDE Asesores SL, QBE Europe SA/NV

Cardiac Output, Low

01/22

12/22

Not yet recruiting

2/3

332

RoW

Levosimendan, Standard care

Chittagong Medical College, Beacon Pharmaceuticals PLC, Pi Research and Development Center, Bangladesh

Acute Decompensated Heart Failure (ADHF)

10/26

12/26

Completed

2/3

190

Europe

Simdax, 2,5 mg/mL, koncentrat do sporz?dzania roztworu do infuzji, GLUCOSUM 5% FRESENIUS, 50 mg/ml, roztw?r do infuzji

Medical University Of Gdansk, Medical Research Agency (Agencja Bada? Medycznych)

Takotsubo syndrome

 

 

Ongoing

2

68

Europe

Levosimendan, Concentrate and solvent for solution for infusion

VieCuri Medical Center, Orion Pharma

Acute Kidney Injury (AKI) in adult ICU patients, Acute Kidney Injury (acute renal failure) in patients admitted to the Intensive Care Unit (ICU), Diseases [C] - Symptoms and general pathology [C23]

 

 

Ongoing

2

20

Europe

COROTROPE, Levosimendan, COROTROPE solución inyectable, SIMDAX 2,5 mg/ml concentrado para solución para perfusión, COROTROPE solución inyectable, SIMDAX 2,5 mg/ml concentrado para solución para perfusión

Fundación de Investigación Biomédica del Hospital Universitario La Paz, Madrid

Este estudio evaluará la eficacia de dos inodilatadores (IND) en el tratamiento del síndrome de bajo gasto postoperatorio (SBGP) en recién nacidos sometidos a cirugía cardiovascular (CCV)

 

 

Not yet recruiting

2

30

Europe

ZIMINO 12,5 mg, Solution for infusion, ZIMINO 2,5 mg/ml (Levosimendan)

APHP, Laboratoire ORION corporation

subarachnoid hemorrhages of aneurysmal origin (HSAa) hémorragies sous-arachnoïdiennes d’origine anévrysmales (HSAa), subarachnoid hemorrhages of aneurysmal origin (HSAa) hémorragies sous-arachnoïdiennes d’origine anévrysmales (HSAa), Body processes [G] - Physiological processes [G07]

 

 

Recruiting

2

6

Europe

Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Inhaled, Levosimendan 2.5 milligram/milliliter Injectable Solutiondose Intravenous

Universitair Ziekenhuis Brussel

Left Ventricular Dysfunction

11/24

01/25

Recruiting

1/2

46

Europe

Cernevit, Pulver zur Herstellung einer Injektions- oder einer Infusionsl?sung, Levosimendan EQL Pharma 2,5mg/ml Konzentrat zur Herstellung einer Infusionsl?sung

Allgemeines Krankenhaus Der Stadt Wien Universitatskliniken, Medical University Of Vienna

Cardiogenic Shock

 

 

1/2

40

Europe

Glukos 5%, Simdax 2,5 mg/ml koncentrat till infusionsv?tska, l?sning

Karolinska University Hospital, Region Stockholm, Swedish Medical Society, Swedish Heart and lung foundation

Cardiac arrest

 

 

Recruiting

1

6

Europe

UZ Brussel

heart failure

 

 

Completed

N/A

96

 

dobutamine ;levosimendan

Zhejiang Hospital; Zhejiang Hospital, The National Natural Science Foundation of China (81401580, 81772051)

Sepsis

 

 

Not yet recruiting

N/A

140

 

None ;None

The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Integrated Thinking Research Fund of China Foundation for International Medical Exchange

Heart-derived shock

 

 

Recruiting

N/A

100

 

Levosimendan alone was used; levosimendan joint participation injection

Shanghai Tongren Hospital Ethics Committee; Tongren Hospital of Shanghai, The research thinking of exchange foundation international medical fund

Acute heart failure

 

 

Not yet recruiting

N/A

48

 

use traditional vasoactive drugsand levosimendan ;use traditional vasoactive drugs

Children's Hospital Affiliated to Capital Institute of Pediatrics; Children's Hospital Affiliated to Capital Institute of Pediatrics, Integrated Thinking Research Fund of Cardiology

Low cardiac output syndrome

 

 

Recruiting

N/A

40

 

Intermittent infusion of intravenous levosimendan (0.2 μg/kg/min, without loading dose) over 6 hours once every 2 weeks ;Standard care with follow-up every 2 weeks

N.A. (PI initiated study; PI: Dr Erik Fung); Level of the institution：, Donation from Synmosa Biopharma Corp. and research funds from The University Grants Committee (Hong Kong) Research Matching Grant Scheme

End-stage heart failure

 

 

Recruiting

N/A

300

Europe

Levosimendan, Interventional, No Levosimendan, Control

Central Hospital, Nancy, France

Levosimendan, Cardiac Surgery, Heart Failure With Reduced Ejection Fraction

07/23

10/23